Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report
R Raman1, P S Aisen, M C Carillo
1Rema Raman, Professor of Neurology, Director of Biostatistics and Recruitment, Alzheimer's Therapeutic Research Institute (ATRI), Keck School of Medicine of USC, University of Southern California, 9860 Mesa Rim Road, San Diego, CA 92121, USA,
Abstract:
As the last opportunity to assess treatment effect modification in a controlled setting prior to formal approval, clinical trials are a critical tool for understanding the safety and efficacy of new treatments in diverse populations. Recruitment of diverse participants in Alzheimer's Disease (AD) clinical trials are therefore essential to increase the generalizability of study results, with diversity broadly described to be representative and inclusive. This representation of study participants is equally critical in longitudinal cohort (observational) studies, which will be key to understanding disease disparities and are often used to design adequately powered AD clinical trials. New and innovative recruitment initiatives and enhanced infrastructure facilitate increased participant diversity in AD clinical studies.
Insights
Recruiting diverse participants for Alzheimer's Disease (AD) clinical trials is essential for ensuring treatment efficacy and generalizability. Innovative recruitment strategies and infrastructure are key to achieving this crucial diversity in AD research.
Area of Science:
- Neuroscience
- Clinical Research
- Public Health
Background:
- Clinical trials are vital for assessing new Alzheimer's Disease (AD) treatments before approval.
- Participant diversity in trials ensures treatment effects are understood across different populations.
- Longitudinal cohort studies are crucial for understanding disease disparities and informing trial design.
Purpose of the Study:
- To emphasize the critical need for diverse participant recruitment in Alzheimer's Disease (AD) clinical trials.
- To highlight the importance of diversity for the generalizability and reliability of AD treatment research.
- To underscore the role of observational studies in identifying health disparities and designing effective AD clinical trials.
Main Methods:
- Review of the importance of participant diversity in clinical trial settings.
- Emphasis on the role of longitudinal cohort studies in AD research.
- Discussion of innovative recruitment initiatives and infrastructure development.
Main Results:
- Diverse participant recruitment enhances the generalizability of clinical trial findings.
- Inclusivity in study populations is critical for understanding treatment effect modification.
- Enhanced recruitment strategies and infrastructure are facilitating increased diversity in AD studies.
Conclusions:
- Achieving broad representation in AD clinical trials is essential for equitable and effective treatment development.
- Innovative approaches to participant recruitment are vital for improving diversity in AD research.
- Diverse and inclusive studies are fundamental to addressing Alzheimer's Disease disparities.
More Related Videos
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...